Aprea Therapeutics (NASDAQ:APRE) Issues Earnings Results, Beats Estimates By $0.11 EPS

Aprea Therapeutics (NASDAQ:APRE) issued its quarterly earnings data on Wednesday. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.11, FiscalAI reports. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 61.03%.

Aprea Therapeutics Stock Performance

Shares of APRE stock opened at $0.68 on Thursday. The firm’s 50 day moving average price is $0.71 and its two-hundred day moving average price is $0.77. Aprea Therapeutics has a 52-week low of $0.55 and a 52-week high of $1.79. The stock has a market cap of $8.46 million, a PE ratio of -0.44 and a beta of 1.52.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new position in Aprea Therapeutics stock. DRW Securities LLC bought a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 120,651 shares of the company’s stock, valued at approximately $103,000. DRW Securities LLC owned 1.73% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

APRE has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Friday, July 17th. Oppenheimer assumed coverage on Aprea Therapeutics in a research report on Thursday, May 7th. They set an “outperform” rating and a $5.00 price objective for the company. Finally, Wedbush dropped their target price on shares of Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating on the stock in a research report on Thursday, May 14th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $4.07.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.